Business Context and Reporting Period
This Form 8-K reports on the 2023 Annual Meeting of Stockholders held by Recursion Pharmaceuticals, Inc. on June 16, 2023. The filing details the voting results for four proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
The following proposals were voted upon at the Annual Meeting:
- Proposal 1 (Election of Directors): Stockholders elected Terry-Ann Burrell, M.B.A., and Christopher Gibson, Ph.D., as Class II directors to serve until the 2026 annual meeting. Both nominees received significant support with over 163 million votes "For" each.
- Proposal 2 (Executive Compensation): The advisory resolution to approve executive compensation was approved. Votes cast were 178,827,946 "For" versus 1,734,461 "Against."
- Proposal 3 (Frequency of Say-on-Pay): Stockholders favored an annual advisory vote on executive compensation. Votes for a 1-year frequency totaled 180,126,697.
- Proposal 4 (Ratification of Auditors): The appointment of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2023, was ratified. Votes cast were 210,585,521 "For" versus 71,005 "Against."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to disclose the results of the shareholder vote.
Important Facts for Investors
- The company successfully ratified Ernst & Young LLP as its auditor for the 2023 fiscal year.
- Shareholders overwhelmingly approved the current executive compensation package and preferred annual say-on-pay votes.
- Two directors were elected to the board for a three-year term ending in 2026.
- No financial performance data or operational updates are included in this specific filing.